



# Animal models for photodynamic therapy (PDT)

## Citation

Silva, Zenildo Santos, Sandra Kalil Bussadori, Kristianne Porta Santos Fernandes, Ying-Ying Huang, and Michael R. Hamblin. 2015. "Animal models for photodynamic therapy (PDT)." Bioscience Reports 35 (6): e00265. doi:10.1042/BSR20150188. <http://dx.doi.org/10.1042/BSR20150188>.

## Published version

<https://doi.org/10.1042/BSR20150188>

## Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:23845280>

## Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

## Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#)



## OPEN ACCESS

# Animal models for photodynamic therapy (PDT)

Zenildo Santos Silva, Jr\*†‡, Sandra Kalil Bussadori†, Kristianne Porta Santos Fernandes†, Ying-Ying Huang\*† and Michael R. Hamblin\*†§<sup>1</sup>

\*Massachusetts General Hospital, Wellman Center for Photomedicine, Boston, MA 02114, U.S.A.

†Harvard Medical School, Department of Dermatology, Boston, MA 02114, U.S.A.

‡Postgraduate Program in Biophotonics Applied to Health Sciences, Nove de Julho University, São Paulo, SP 02117-010, Brazil

§Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, U.S.A.

## Synopsis

Photodynamic therapy (PDT) employs non-toxic dyes called photosensitizers (PSs), which absorb visible light to give the excited singlet state, followed by the long-lived triplet state that can undergo photochemistry. In the presence of ambient oxygen, reactive oxygen species (ROS), such as singlet oxygen and hydroxyl radicals are formed that are able to kill cancer cells, inactivate microbial pathogens and destroy unwanted tissue. Although there are already several clinically approved PSs for various disease indications, many studies around the world are using animal models to investigate the further utility of PDT. The present review will cover the main groups of animal models that have been described in the literature. Cancer comprises the single biggest group of models including syngeneic mouse/rat tumours that can either be subcutaneous or orthotopic and allow the study of anti-tumour immune response; human tumours that need to be implanted in immunosuppressed hosts; carcinogen-induced tumours; and mice that have been genetically engineered to develop cancer (often by pathways similar to those in patients). Infections are the second biggest class of animal models and the anatomical sites include wounds, burns, oral cavity, ears, eyes, nose etc. Responsible pathogens can include Gram-positive and Gram-negative bacteria, fungi, viruses and parasites. A smaller and diverse group of miscellaneous animal models have been reported that allow PDT to be tested in ophthalmology, atherosclerosis, atrial fibrillation, dermatology and wound healing. Successful studies using animal models of PDT are blazing the trail for tomorrow's clinical approvals.

**Key words:** autochthonous, cancer, genetically-engineered mouse model, infection, orthotopic tumour, photodynamic therapy, subcutaneous tumour, xenograft.

Cite this article as: Bioscience Reports (2015) 35, e00265, doi:10.1042/BSR20150188

## INTRODUCTION


Photodynamic therapy (PDT) employs non-toxic dyes called photosensitizers (PSs), which absorb visible light of the correct wavelength to first give the excited singlet state, followed by a transition to the long-lived excited triplet state that can undergo photochemistry [1]. In the presence of molecular oxygen, the photochemical reactions produce a variety of reactive oxygen species (ROS) including singlet oxygen and hydroxyl radicals. These ROS cause oxidative damage to proteins, lipids and nucleic acids and leading to cell death by necrosis and/or apoptosis (Figure 1), PDT was originally developed as a cancer treatment, but has subsequently been investigated as a treatment for choroidal neovascularization secondary to age-related macular degeneration, for a range of localized infections and for disorders related to dermatology and immunology.

When PDT is used as a tumour therapy, the PS is usually injected IV (intravenous), followed by a waiting period known as the 'drug light interval' to allow the tumour to accumulate at the site of the tumour. Light can be delivered to the tumour site either by shining a focused spot of light on to the tissue (which can be done endoscopically) or by inserting fibre optics into the tumour tissue in a technique called interstitial light delivery. The anti-tumour effects of PDT result from the combination of three different *in vivo* mechanisms, namely direct PDT cytotoxicity to tumour cells, destruction of the tumour microvasculature and induction of an acute local inflammatory response leading to activation of the host immune system (Figure 2).

Many different types of photoactivable molecules have been synthesized and tested as possible PDT agents. These PS are often based on the tetrapyrrole backbone such as porphyrins, chlorins, bacteriochlorins and phthalocyanines (Figure 3). The


**Abbreviations:** ALA, aminolevulinic acid; CAM, chorioallantoic membrane; DMBA, 7,12-dimethyl-benz(a)anthracene; GEMM, Genetically-engineered mouse model; MHC, major histocompatibility complex; PDT, photodynamic therapy; PPIX, protoporphyrin IX; PS, photosensitizer; ROS, reactive oxygen species; SCID, severe combined immunodeficient.

<sup>1</sup> To whom correspondence should be addressed (email hamblin@helix.mgh.harvard.edu).




**Figure 1 Jablonski diagram**

When light ( $h\nu$ ) is absorbed by the PS the electron moves from a non-excited, low-energy singlet state into a high-energy singlet state. This excited state can lose energy by emitting a photon (fluorescence) or by internal conversion (non-radiative decay). The process known as inter-system crossing, involves flipping of the spin of the high-energy electron, leading to a long-lived excited triplet state. In the presence of molecular oxygen, superoxide and hydroxyl radicals are formed in type I reactions and singlet oxygen in type II reactions. These ROS can damage most types of biomolecules (proteins, lipids, nucleic acids).



**Figure 2 Mechanisms of PDT of an experimental tumour**

PS is injected IV followed by a time delay [drug-light interval (DLI)]. Then activating red light is delivered to the tumour cause the production of ROS. The ROS can cause direct tumour cell killing by necrosis or apoptosis, shut-down the tumour blood supply and activate neutrophils (PMN) and dendritic cells (DC) that stimulates an anti-tumour immune response.



**Figure 3** Chemical structures of some representative PS that have been applied in both pre-clinical animal models and also in clinical studies

Shown are Photofrin, conversion of ALA to PPIX, Foscan or mTHPC (m-tetrahydroxyphenylchlorin), Verteporfin or BPD-MA (benzoporphyrin derivative monoacid ring A), TOOKAD (palladium bacteriopheophorbide) soluble and methylene blue.

latter three structures possess strong light absorption bands at wavelengths longer than 650 nm and are therefore well suited to the so-called 'optical window' required for good tissue penetration of light. Highly effective PS require an absorption maximum between 650 and 800 nm to avoid the absorption by the endogenous tissue chromophores, such as haemoglobin, whereas still having enough photon energy to carry out photochemistry. The chemical structure of the PS molecule can be tailored to provide high cell uptake, selectivity for cancer cells and endothelial cells and to provide photostability (i.e. resistance to photobleaching). A recent alternative approach is to attach the PS covalently or non-covalently to biomolecules that possess a marked targeting ability towards cancer cells, such as monoclonal antibodies or specific peptides. A popular alternative to traditional PS is to use 5-aminolevulinic acid (ALA), a biochemical precursor to the endogenous PS, protoporphyrin IX (PPIX) [2].

### Cancer

Since the first pioneering studies of PDT to cure tumours in the 1970s by Diamond et al. [3] and by Dougherty et al. [4], cancer has been the leading indication for PDT. Although much research has been carried out in cell culture studies *in vitro* and, more recently, in 3D tissue culture models [5,6], more complex systems such as laboratory animals are required to demonstrate that these new PDT approaches could eventually work in clinical situations. The next sections of this review will give an overview of the different animal models that have been employed in studies of PDT for cancer.

### Chorioallantoic membrane


One very simple intermediate model that lies in between *in vitro* cell culture and laboratory animals is the chorioallantoic membrane (CAM) of fertilized chicken eggs that have had a window

of eggshell removed. This model allows the growth of tumour cells that are applied as a suspension on to the surface of the membrane and turn into ‘tumours’ that go on to develop their own blood supply by the process of angiogenesis (in a similar fashion to real tumours in mice). PS can be injected into these blood vessels, allowed to accumulate in the tumours and then light can easily be delivered and changes in blood flow in the tumour and normal vessels can be observed in real time. PS can also be topically applied to the xenografted tumours on the CAM. The advantages of this model include the ease of *in vivo* microscopy to study PDT-induced vascular damage and the lack of regulatory controls on experiments involving eggs [7–11].

### Subcutaneous syngeneic mouse and rat tumours

Using subcutaneous tumours in laboratory mice is very common among investigators aiming to test various PDT regimens (Table 1). There are a large number of mouse tumour cell lines available, which differ in the type of tissue or organ that the tumour originated from and also in the particular syngeneic inbred mouse strain that the tumours belong to. Individual laboratory mouse strains (*Mus musculus*) have particular combinations of major histocompatibility complexes (MHCs; MHC class I such as H2B and MHC class II such as Ia) and the tumour cells should have the same combination of MHC molecules as the host mouse to allow them to grow without instant rejection. This syngeneic mouse tumour approach is often used because the mice have intact immune systems and, therefore, immunology and anti-tumour immunity effects after PDT can be studied. There are many inbred mouse strains available (over 400), but the most commonly used examples in anti-cancer PDT studies are BALB/c (albino), C57BL/6 (black), C3H (brown) and DBA2 (grey). Tumour types include adenocarcinoma lines (colon, lung, breast, pancreas etc.), squamous cell carcinoma, fibrosarcoma, lymphoma, melanoma, malignant glioma and many others. Rat tumour cell lines are less common than murine tumour lines, but there are several known belonging to inbred laboratory rat strains (*Rattus norvegicus*) such as Wistar, Lewis, Sprague–Dawley, Fischer 344 etc. Subcutaneous tumours differ in their rate of growth, degree of vascularization, amount and kind of tumour stroma and potential to form spontaneous metastasis. In addition to injecting the tumour cells beneath the skin, they can also be injected between the layers of the epidermis and dermis to form intradermal tumours. It has been shown that intradermal tumours are more easily recognized by the immune system compared with subcutaneous tumours [12]. In some cases, investigators mix the tumour cells with a preparation of extracellular matrix, called Matrigel, before injection and it has been shown that this can make a difference in the response of the tumour to PDT [13]. Many investigators transplant tumours from one animal to another by inserting small pieces obtained from an excised whole tumour under the skin of the next animal.

PDT of subcutaneous mouse tumours is usually carried out by IV injection of the PS (often in the tail vein) followed after a certain period of time by light delivery to the tumour including a certain amount of surrounding normal tissue. This time period,



**Figure 4** Image of a subcutaneous mouse tumour (EMT6 breast carcinoma in BALB/c mouse) treated with PDT (iv BPD 1 mg/kg, 15 min drug-light interval, 100 J/cm<sup>2</sup> 690 nm light)

Three days post-PDT, a circumscribed black eschar is visible that will heal with no detectable scar after 2 weeks.

called the ‘drug light interval’, is an important parameter that governs the amount of vascular damage that occurs during the treatment and therefore whether the PDT regimen is ‘vascular’ or ‘cellular’. Less common is the injection of the PS into the abdominal cavity (intraperitoneal [14] or directly into the tumour (intra-tumoural [15])). With the recent rise in the study of PDT mediated by a wide range of nanoparticles and multifunctional nanostructures, the use of intra-tumoural injection has become more common. This is because the pharmacokinetics and bio-distribution of these engineered nanostructures has as yet not been much investigated.

The response of subcutaneous tumours depends on whether the PDT regimen is predominantly vascular or cellular. For vascular PDT, a circumscribed black eschar usually appears approximately 2 days post PDT (Figure 4). For cellular PDT, it is common for the tumour volume to shrink without such a visible black eschar. In many cases, a pronounced swelling of the tissue is seen soon after completion of the illumination, due to the acute inflammatory reaction. The duration of the tumour response depends on many factors. In the case of a marked immune response occurring after PDT, tumours do not recur and the animals are regarded as cured after 90 days of being tumour-free. Local tumour recurrence can occur after PDT and this recurrence often takes the form of an annulus or ‘doughnut’ of tumour surrounding the original tumour. The reason for the morphology of this recurrence is not completely understood, but may involve the presence of cancer stem cells in the periphery of the original tumour at the ‘invasive front’ [16].

### Human xenograft tumours

Much more is known about the molecular biology and tumour biology of human tumours than is known for analogous mouse tumours. A large amount of knowledge about mutations, oncogenes, impaired tumour suppressor pathways, growth factors, epigenetics and so on, is more or less specific for human tumours and much less is known about the effects of these factors in mouse tumours. The discovery of immunosuppressed mice that can be either athymic nude mice or the severe combined immunodeficient (SCID) mice that are T- and B-cell-deficient, allows the engraftment of human tumour cells known as ‘xenografts’ (or sometimes xenographs). Due to the increased susceptibility of these mice to infections, the cell

**Table 1 Subcutaneous syngeneic mouse/rat tumours that have been used for PDT**

Abbreviations: AIS2Pc, aluminum phthalocyanine disulfonated (adjacent); AO, acridine orange; BPD-MA, benzoporphyrin derivative monoacid ring A; DLI, drug light interval; HPPH, hexyl-pyropheophorbide; inj, injected; mTHPC, m-tetrahydroxyphenylchlorin; TPP, tetraphenylporphyrin.

| Cell line          | Cancer type                    | Mouse strain       | PDT regimen                                                                              | References |
|--------------------|--------------------------------|--------------------|------------------------------------------------------------------------------------------|------------|
| EMT6               | Mammary sarcoma                | BALB/c             | Photofrin, DLI 24 h, 630 nm, 110 J/cm <sup>2</sup> , 130 mW/cm <sup>2</sup>              | [38]       |
| CT26 (c26, colo26) | Colon adenocarcinoma           | BALB/c             | Pheophorbide HPPH, DLI 24 h, 665 nm, 100 J/cm <sup>2</sup> , 75 mW/cm <sup>2</sup>       | [39]       |
| DA3 <sup>Hi</sup>  | Breast adenocarcinoma          | BALB/c male mice   | Hypericin, inj IP, DLI 6 h, 400–700 nm, 60 J/cm <sup>2</sup> , 20 min                    | [40]       |
| MS-2               | Fibrosarcoma                   | BALB/c             | Phthalocyanine AIS2Pc, DLI 24 h, 670 nm, 60 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>   | [41]       |
| 4T1                | Breast cancer                  | BALB/c female mice | Verteporfin BPD-MA, DLI 24 h, 690 nm, 120 J/cm <sup>2</sup>                              | [42]       |
| B16                | Melanoma                       | C57BL/6            | Porphyrin TPP, DLI 9 h, 630 nm, 90 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>            | [43]       |
| LLC                | Lewis lung adenocarcinoma      | C57BL/6            | Photofrin, DLI 24 h, 630 nm, 150 J/cm <sup>2</sup> , 90 mW/cm <sup>2</sup>               | [44]       |
| TC1                | Lymphoma                       | C57BL/6            | Radachlorin, DLI 3 h, 662 nm, 300 J/cm <sup>2</sup>                                      | [45]       |
| RIF1               | Radiation-induced fibrosarcoma | C3H                | Photofrin, DLI 24 h, 400 nm, 135 J/cm <sup>2</sup>                                       | [46]       |
| FsaR               | Fibrosarcoma                   | C3H/HeN            | Photofrin, DLI 24 h, 630 nm, 150 J/cm <sup>2</sup> , 110 mW/cm <sup>2</sup>              | [47]       |
| SCCVII             | Squamous cell carcinoma        | C3H                | Foscan mTHPC, DLI 24 h, 650 nm, 50 J/cm <sup>2</sup> , 90 mW/cm <sup>2</sup>             | [48]       |
| DLM-8              | Osteosarcoma                   | C3H                | Acridine orange AO, DLI 2 h, xenon flash lamp, 15 J per pulse, 60 Hz, 10 min             | [49]       |
| P815               | Mastocytoma                    | DBA/2              | Verteporfin BPD-MA, DLI 15 min, 690 nm, 120 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>   | [50]       |
| Sarcoma 180        | Sarcoma                        | ICR outbred        | Haematoporphyrin, inj IP, DLI 24 h, 635 nm, 30 J/cm <sup>2</sup> , 26 mW/cm <sup>2</sup> | [51]       |
| NXS2               | Neuroblastoma                  | Female A/J         | Pheophorbide HPPH, DLI 24 h, 665 nm, 48 J/cm <sup>2</sup> , 7 mW/cm <sup>2</sup>         | [52]       |
| VMDK               | Glioma                         | VM                 | Porphyrin mTHPP, DLI 24 h, 648 nm, 20 J/cm <sup>2</sup> , 300 mW/cm <sup>2</sup>         | [53]       |
| Walker 256         | Carcinosarcoma                 | Wistar male rats   | Porphyrin TSPR, DLI 24 h, 685 nm, 50 J/cm <sup>2</sup> , 25 W/cm <sup>2</sup>            | [54]       |
| MatLyLu (Dunning)  | Prostate                       | Copenhagen rats    | Verteporfin BPD, DLI 1 h, 690 nm, 50 J/cm <sup>2</sup> , 50 mW/cm <sup>2</sup>           | [55]       |

lines must be free of mouse pathogens and the mice must be kept in specific pathogen-free conditions. Even so, innate immunity, particularly natural killer (NK) cells and tumouricidal macrophages, can limit tumour growth and prevent metastasis in nude mice [17]. A large number of human cancer cell lines grown as xenograft tumours grown in a subcutaneous location in either nude mice or SCID mice have been subjected to PDT (Table 2).

### Orthotopic syngeneic mouse and rat tumours

There has been criticism levelled at the widespread use of subcutaneous tumours in PDT research, to the effect that they fail to replicate the normal biology of human tumours by not being situated in their organ of origin (orthotopic) and are therefore

not subject to the appropriate environmental cues and signalling from the host tissue. The blood supply that develops to supply the tumour is very different in orthotopic models and the propensity to spontaneously metastasize is also higher. For instance brain tumours behave very differently when implanted in the brain, than when grown subcutaneously. Investigators have therefore injected the tumour cells into the tissue of the organ of origin in the mouse or rat. This procedure may need a surgical approach that depends on the actual organ to be implanted with the tumour. This has been done with colon carcinomas (into the wall of the colon), renal cell cancers (into the kidney), mammary carcinomas (into the mammary fat pad), bladder carcinomas (into the bladder wall), prostate carcinoma (into the prostate), pancreatic carcinoma (into the pancreas) and lung cancer (into the bronchi). Moreover, the actual PDT treatment approach necessitates being

**Table 2 Orthotopic syngeneic mouse/rat tumours**

Abbreviations: DLI, drug light interval; EGF<sub>pep</sub>-AuNP-Pc4, a conjugate between an epidermal growth factor peptide, gold nanoparticles, and silicon phthalocyanine; mTHPC, m-tetrahydroxyphenylchlorin.

| Cancer type   | Cell line             | Mouse/rat model          | PDT regimen                                                                                                   | References |
|---------------|-----------------------|--------------------------|---------------------------------------------------------------------------------------------------------------|------------|
| Prostate      | TRAMP-C2              | Albino male C57BL/6 mice | 5-ALA, DLI 72 h, 635 nm, 100 J/cm <sup>2</sup> , 200 mW/cm <sup>2</sup>                                       | [56]       |
| Bladder       | AY-27 cells           | Female Fischer F344 rats | ALA, DLI 2 h, 514 nm, 20 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                                           | [57]       |
| Prostate      | R3327-MatLyLu Dunning | Male Copenhagen rats     | Verteporfin DLI 15 min–3 h, 690 nm, 50 J/cm <sup>2</sup> , 50 mW/cm <sup>2</sup> , 1000 s                     | [58]       |
| Glioma/brain  | 9L.E29                | Female athymic mice      | Phthalocyanine, EGF <sub>pep</sub> -Au NP-Pc 4; DLI 4 h, 672 nm, 50 J/cm <sup>2</sup> , 0.1 W/cm <sup>2</sup> | [59]       |
| Breast cancer | 4T1                   | BALB/c female mice       | Photofrin, DLI 120 h, 635 nm, 100 J/cm <sup>2</sup> , 416.7 mW/cm <sup>2</sup>                                | [60]       |
| Glioma/brain  | C6-9                  | Sprague–Dawley male rats | Foscan, mTHPC DLI 48 h, 652 nm, 20 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                                 | [61]       |
| Glioma/brain  | BT4C                  | BD-IX rats               | ALA (ip), 5 h DLI, 632 nm, 26 J, 30 mW                                                                        | [62]       |

able to get the light to the tumour, which is more difficult for orthotopic tumours.

Orthotopic tumours used to test PDT can either be syngeneic in mice or rats or can be xenografts (Table 3). There is one rabbit tumour that has been quite often used to create orthotopic tumour models in a medium sized animal, the New Zealand white rabbit. The VX2 tumour cell line was originally derived from a virus-induced skin papilloma [18], but has been widely used to produce tumours in the liver [19], the pancreas [20] and the brain [21], all of which have been treated with PDT.

### Autochthonous tumours

Tumours that arise naturally in the host are called ‘autochthonous’. In the laboratory studies, these tumours are usually induced by application of chemical carcinogens, but viruses and physical carcinogenic stimuli (for instance UV radiation) have also been used. These models effectively recapitulate the time-dependent and multi-stage progression of cancer formation in response to relevant environmental carcinogens and tumour-promoting agents [22]. These models utilize the topical, intraperitoneal, or oral administration of a variety of polycyclic aromatic hydrocarbons or reactive organic chemicals either alone or in combination with known tumour promoters, such as phorbol esters, to induce specific cancers in a variety of immunocompetent mice, rats and hamsters. The susceptibility to chemical carcinogenesis and the resultant tumour incidence and multiplicity varies with the protocol, the dosage of carcinogens and promoters and the age and strain of the rodents used. The Syrian golden hamster model of oral dysplasia and cancer caused by repeated application of 7,12-dimethyl-benz(a)anthracene (DMBA) is particularly noteworthy, as hamsters are chosen because of the presence of the cheek pouch as an example of oral mucosa that is relatively easily manipulated [23]. Moreover, the lesions undergo a predictable progression through hyperplasia, mild and severe dysplasia before tumours begin to appear after approximately 12 weeks

of application 3× per week. (Table 4) lists some autochthonous tumour models that have been employed in PDT studies.

### Genetically-engineered mouse models of cancer

Genetically-engineered mouse models (GEMMs) of cancer have been constructed to more closely mimic the development of human disease in a predictable manner [24]. Since the 1980s, several types of GEMMs have been used, including transgenic, knockout and knockin mouse models [25]. Mutant mice that express oncogenes or dominant-negative tumour-suppressor genes governed by ectopic promoter and enhancer elements can be generated by pronuclear injection of cDNA constructs that contain promoter elements designed to restrict expression to certain tissues. GEMM can be produced by the direct injection of fertilized oocytes or by lentiviral transduction of embryonic stem cells. Targeted transgenesis provides an attractive alternative to random transgenesis by using integration mediated by recombination at specific sites allowing insertion of only a single copy of the transgene [26].

Many GEMM models of cancer have been developed including lung, colon, stomach, oesophagus, pancreas, liver, breast, ovary, prostate, bladder, kidney, brain and skin [25]. In some of these models, an additional application of a carcinogen needs to be used to actually initiate tumour development. Examples of these additional insults could be UV irradiation to initiate skin cancer or injection of dextran sulfate to initiate colon carcinogenesis. Despite the large number of GEMM, as yet only a few of these have been used to test PDT. These are listed in Table 5.

### In vivo imaging

In recent years, there has been an explosion of non-invasive imaging techniques applied to laboratory studies of cancer and anti-cancer therapy. Many of these *in vivo* imaging modalities are based on adaptation of those clinical modalities that are familiar to oncologists to be used in small animals. This classification includes such modalities as micro-positron emitting tomo-

**Table 3 Xenograft mouse or rat tumours, Route: IV, IP, IT**

Abbreviations: AIOH-PC, hydroxyaluminum-phthalocyanine; BPD-MA, benzoporphyrin derivative monoacid ring A; CD1, a strain of mice; DLI, drug light interval; Ncr, another strain of mice; NSCLC, non small cell lung cancer; Pd, TOOKAD, palladium bacteriopheophorbide; sc, subcutaneous; SCC, squamous cell carcinoma.

| Cell line         | Cancer type              | Animal model                    | PDT regimen                                                                                           | References |
|-------------------|--------------------------|---------------------------------|-------------------------------------------------------------------------------------------------------|------------|
| OVCAR3            | Ovarian                  | Nude mice                       | Photofrin, DLI 24 h, 635 nm, 200 J/cm <sup>2</sup>                                                    | [63]       |
| OVCAR5            | Ovarian                  | Nude mice                       | Verteporfin, BPD-MA, DLI 90 min, 690 nm, 40 J, 320 s                                                  | [64]       |
| AsPC-1 and Panc-1 | Pancreas                 | Male SCID mice                  | Verteporfin, DLI 1 h, 690 nm, 40 J/cm <sup>2</sup> , 74mW/cm <sup>2</sup>                             | [65]       |
| LNCaP             | Prostate                 | SCID mice                       | Liposomal BPD, DLI 1 h, 690 nm, 100 J/cm <sup>2</sup>                                                 | [66]       |
| WISH-PC237        | Prostate                 | Male CD1 nude mice              | Pd-bacteriopheophorbide TOOKAD, DLI zero, 650–800 nm, 360 J/cm <sup>2</sup> , 30 min                  | [67]       |
| Eca109            | Oesophageal SCC          | Nude mice (sc or orthotopic)    | Photofrin, DLI 24 h, 630 nm, 135 J/cm <sup>2</sup> , 75 mW/cm <sup>2</sup>                            | [68]       |
| A549              | Lung cancer (NSCLC)      | nude mice                       | Factor VII-targeted Sn(IV) chlorin e6 conjugate, 635 nm, 72 J/cm <sup>2</sup>                         | [69]       |
| H460              | Lung cancer (NSCLC)      | Ncr-nu/nu female mice           | Photochlor HPPH, DLI 24 h, 661 nm, 200 J/cm. 150 mW/cm                                                | [70]       |
| FaDu              | Head and neck SCC        | Female nu/nu CByJ.Cg-Foxn1nu/J. | HPPH, DLI 24 h, 665 nm, 48 J/cm <sup>2</sup> , 7 mW/cm <sup>2</sup>                                   | [52]       |
| MDA-MB 231        | Mammary carcinoma        | Nude mice                       | Phthalocyanine, AIOH-PC, DLI 10 min, 635 nm, 100 J/cm <sup>2</sup> , 0.97 W, 7 min.                   | [71]       |
| MCAIV             | Breast                   | Female SCID                     | Pyropheophorbide MV6401, DLI 15 min, 664 nm, 5 J/cm <sup>2</sup> , 50 mW/cm <sup>2</sup> .            | [72]       |
| HT29              | Liver                    | Female Swiss nude mice          | Monoclonal antibody chlorin(e6) conjugate, 17.1A-pl-ce6-succ, DLI 3 h, 666 nm, 80 J, 100 mW, 13.3 min | [73]       |
| NPC               | Nasopharyngeal carcinoma | BALB/c nude mice                | 5-ALA, DLI 3.5 h, 630 nm, 100 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                              | [74]       |

**Table 4 Autochthonous tumours**

Abbreviations: CBA, a strain of mice; DLI, drug light interval; FVB, another strain of mice; LED, light emitting diode; NMRI–HR–HR, another strain of mice; TPA, 12-O-Tetradecanoylphorbol-13-acetate.

| Cancer type           | Animal species                    | Carcinogen                                      | PDT regimen                                                                                        | References |
|-----------------------|-----------------------------------|-------------------------------------------------|----------------------------------------------------------------------------------------------------|------------|
| Oral cancer/dysplasia | Male Wistar rats                  | 4-Nitroquinoline-1-oxide (4NQO)                 | Photofrin, DLI 24 h, 625 nm, 100 J/cm <sup>2</sup> , 60 mW/cm <sup>2</sup> .                       | [75]       |
| Oral cancer/dysplasia | Male CBA mice                     | 4-Nitroquinoline-1-oxide (4NQO)                 | ALA, DLI 5 h, 630 nm, 200 J/cm <sup>2</sup> , 125 mW/cm <sup>2</sup>                               | [76]       |
| Oral cancer/dysplasia | Syrian Golden Hamster             | DMBA                                            | ALA, DLI 2.5 h, LED 638 nm, 275 J/cm <sup>2</sup> , 200 mW/cm <sup>2</sup>                         | [77]       |
| Oral cancer/dysplasia | Syrian Golden Hamster             | DMBA                                            | Topical Photosan, DLI 16 min, 640 nm, 100 J/cm <sup>2</sup> , 320 mW/cm <sup>2</sup> , 313 s       | (72)       |
| Mammary tumours       | Virgin Sprague–Dawley female rats | DMBA                                            | Photogem® haematoporphyrin, DLI 24 h, LED 635 nm, 200 J/cm <sup>2</sup> , 180 mW/cm <sup>2</sup> . | [78]       |
| Skin tumour           | FVB/N mice                        | DMBA/12-o-tetradecanoylphorbol-13-acetate (TPA) | ALA, DLI 48 h, 635 nm, 120 J/cm <sup>2</sup> , 120 mW/cm <sup>2</sup>                              | [79]       |
| Skin tumour           | female hairless mice (NMRI–HR–HR) | UV irradiation-induced tumour                   | ALA-Me, DLI 4 h, 630–636 nm, 40 J/cm <sup>2</sup> , 20 mW/cm <sup>2</sup>                          | [80]       |

graphy (microPET) [27], micro-single photon micro-computed tomography (micro-SPECT) [28], micro-computed tomography ( $\mu$ CT) [29], high resolution ultrasound [30], photoacoustic tomography (PAT) [31]. However, another large group of small animal

*in vivo* imaging modalities relies upon genetically-encoded reporter molecules and falls into the category of molecular imaging. The two most often used modalities in this class are (1) *in vivo* fluorescence imaging relying on engineered fluorescent protein

**Table 5 GEMM**

Abbreviations: DLI, drug light interval; FVB, another strain of mice.


| Tumour                         | GEMM                                                                           | Inducible            | PDT regimen                                                                                        | References |
|--------------------------------|--------------------------------------------------------------------------------|----------------------|----------------------------------------------------------------------------------------------------|------------|
| Breast                         | Male FVB/NTgN(WapHRAS)69LInYSJL                                                | No                   | Foscan-PEG, SC102; DLI 96 h, 652 nm, 40 J/cm <sup>2</sup>                                          | [81]       |
| Breast                         | FVB.Cg- Tg(WapHRAS)69LIn Chr Y <sup>SJL</sup> /J                               |                      | 5-ALA for fluorescence detection of three different BrCa. DLI 75 min                               | [82]       |
|                                | FVB/N-Tg(MMTV-PyVT)634Mul/J                                                    |                      |                                                                                                    |            |
|                                | C57BL/6J-Tg(WapTAG)1Knnw                                                       |                      |                                                                                                    |            |
| Pancreas ductal adenocarcinoma | LSL-KRasG12D-p53-floxed-Pdx-1-Cre                                              | No                   | Cathepsin-E cleavable ALA, DLI 1 h, 652 nm, 10 J/cm <sup>2</sup> , 50 mW/cm <sup>2</sup> , 3.5 min | [83]       |
| Basal cell carcinoma           | B6C3Fe-a/a-Ptchmes/ + B6C3Fe-a/a-Ptchmes/ + B6C3Fe-a/a-Ptch <sup>mes</sup> / + | UV exposure 20 weeks | MAL, DLI 3 h, 550 nm, 650 Hz, 7 J/cm <sup>2</sup> , 5 mW/cm <sup>2</sup>                           | [84]       |
| Melanoma                       | MT-ret transgenic 304/B6                                                       | No                   | 5-ALA, DLI 3 h, 630 nm, 200 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                             | [85]       |
| Colon dysplasia                | C57BL/6J-Apc(Min)                                                              | Dextran sulfate      | Oral ALA for fluorescence detection of colon tumours, DLI 3 h                                      | [86]       |

reporters such as GFP; and (2) *in vivo* bioluminescent imaging relying on engineered luciferase reporters such as the firefly or marine luciferase enzymes.

## Infections

After cancer, infections represent the next most frequent application of PDT. The use of PDT against infections is motivated by the widespread and growing problem of antibiotic resistance, often called ‘the single biggest problem facing global health’ [32]. A very large number of studies have been published on the use of a wide variety of PS to kill or inactivate numerous classes of microorganisms including Gram-positive bacteria, Gram-negative bacteria, fungi, parasites and viruses. However, the number of studies on PDT for actual infections in animal models is much more limited (Table 6). Traditional methods for quantifying infection involve the killing of animals at various time-points, removal of the infected tissue, homogenization, serial dilution, plating on agar and colony counting. In recent years, the experimental study of PDT for infections has been facilitated by the use of *in vivo* bioluminescence imaging to non-invasively monitor the progression of the infection. Sensitive cameras can record non-invasively, in real time and with longitudinal monitoring, the anatomical location and growth of infectious microorganisms in living hosts [33]. Figure 5 shows an example of the use of this bioluminescence imaging technique to monitor PDT of a Gram-negative *Escherichia coli* infection mediated by pL-ce6 conjugate and red light, in excisional wounds on the back of BALB/c mice [34].

An interesting alternative animal model to study the pathogenesis and therapy of infections is the use of invertebrate hosts [35]. The invertebrate host that has been most frequently used is the larva of *Galleria mellonella*, the greater wax moth. The



**Figure 5** Set of images showing bioluminescence bacteria (*E. coli*) infecting incisional wounds on the back of BALB/c mice treated with PDT mediated by pL-ce6 and 660 nm light

(A) Bioluminescent bacteria added to the wounds. (B) PS (pL-ce6 conjugate) is added to wounds 1 and 4. (C) Red (660 nm, 45 J/cm<sup>2</sup>) light is delivered to wounds 3 and 4 and a loss of bioluminescence is observed in wound 4. (D) At the completion of the light delivery (120 J/cm<sup>2</sup>), the bioluminescence in wound 4 (PDT) has been totally eliminated.

pathogens are injected into the larva, followed by injection of the PS and then by light delivery. This has been reported for *Enterococcus faecium* [36] and for *Candida albicans* [37] both of which were treated with methylene blue and red light.

## Miscellaneous indications

There has been a diverse range of diseases other than cancer and infections that have been treated with PDT in animal models. Some of these are listed in Table 7.

**Table 6 PDT of infections in animal models**

Abbreviations: BCG, Bacillus Calmette-Guerin; BPD, benzoporphyrin derivative; DLI, drug light interval; IP, intraperitoneal; LED, light emitting diode; MB, methylene blue; MRSA, methicillin-resistant *Staphylococcus aureus*; PEI, polytheleneimine; TBO, toluidine blue O.

| Animal model and application                                         | Pathogenic microorganism                                        | PDT Regimen                                                                                           | References |
|----------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------|
| Subcutaneous injection of bacteria into dorsal skin of mice          | <i>Pseudomonas aeruginosa</i>                                   | Sn(IV) chlorin, DLI 15 min, 630 nm, 100 mW/cm <sup>2</sup> , 1600 s                                   | [87]       |
| Bacteria topically applied to burns in guinea pigs                   | MRSA methicillin resistant <i>Staphylococcus aureus</i>         | Haemin/deuteroporphyrin, DLI 1 h, broad-band white, 8 mW/cm <sup>2</sup> , 10 min                     | [88]       |
| Bacteria topically applied to excisional wounds on the backs of mice | Bioluminescent <i>E. coli</i>                                   | Poly-L-lysine-chlorin(e6), DLI 0–30 min, 660 nm, 300 mW, 40 J/cm <sup>2</sup> , 50 mW/cm <sup>2</sup> | [89]       |
| Topical application to excisional wounds on the backs of mice        | Bioluminescent <i>P. aeruginosa</i>                             | Poly-L-lysine-chlorin(e6), DLI 30 min, 660 nm, 40 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>          | [90]       |
| Bacteria injected into the muscles of mice                           | Bioluminescent <i>S. aureus</i>                                 | pL-ce6, DLI 30 min, 665 nm, 160 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                            | [91]       |
| Infected burns in mice                                               | <i>S. aureus</i>                                                | Cationic porphyrin Sylsens B, 635 nm, 423 J/cm <sup>2</sup> , 84 min                                  | [92]       |
| Infected burns in mice                                               | <i>Acinetobacter baumannii</i>                                  | PEI-ce6, DLI 15 min, 660 nm, 240 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                           | [93]       |
| Oral candidiasis in nude mice                                        | <i>C. albicans</i>                                              | MB, DLI 10 min, 664 nm, 275 J/cm, 400 mW, 687.5 s                                                     | [94]       |
| Leishmaniasis in hamsters                                            | <i>Leishmania amazonensis</i>                                   | MB, DLI 10 min, LED, 663 nm, 12 J/cm <sup>2</sup> , 5 mW/cm <sup>2</sup> , 1 h.                       | [95]       |
| Subcutaneous granulomas of tuberculosis in male BALB/c mice          | <i>Mycobacterium bovis</i> BCG                                  | Verteporfin, BPD, DLI 1 h, 690 nm, 60 J/cm <sup>2</sup> and 100 J/cm <sup>2</sup>                     | [96]       |
| Otitis media with effusion (OME) in Mongolian gerbils                | <i>Streptococcus pneumoniae</i> or <i>Hemophilus influenzae</i> | Haematoporphyrin, DLI 6 h, 632 nm, 90 J, 100 mW, 15 min                                               | [97]       |
| Periodontal disease in Wistar rats.                                  | Natural Gram-negative anaerobic bacteria                        | TBO, DLI 1 min, 660 nm, 57.14 J/cm <sup>2</sup>                                                       | [98]       |
| Osteomyelitis bacterial infection in Sprague–Dawley rats             | Bioluminescent <i>S. aureus</i>                                 | IP ALA, DLI 4 h, 635 nm, 75 J/cm <sup>2</sup> , 250 mW/cm <sup>2</sup>                                | [99]       |
| Murine bacterial arthritis in knee                                   | Bioluminescent methicillin-resistant <i>S. aureus</i> (MRSA)    | Intra-articular MB, 660 nm, DLI 5 min, 160 J/cm <sup>2</sup> , 100 mW/cm <sup>2</sup>                 | [100]      |
| Oral wound infections in Wistar rats                                 | <i>Streptococcus spp.</i> and <i>Actinomyces viscosus</i>       | TBO, 635 nm, DLI 10 min, 48 J/cm <sup>2</sup> , 246 mW, 2 min                                         | [101]      |
| Infection in excisional wounds of mice                               | <i>Vibrio vulnificus</i>                                        | TBO, DLI 30 min, 560–780 nm, 200 J/cm <sup>2</sup> , 80 mW/cm <sup>2</sup> , 20 min                   | [102]      |

## CONCLUSIONS

It is almost a universally accepted axiom in cancer research that enormous numbers of mice and rats have been cured of cancer by a wide range of experimental therapeutics, but the translation into clinical practice has been disappointing more often than not. Nevertheless, the importance of designing and select-

ing the most appropriate animal models to investigate the ever-increasing range of new experimental therapeutic approaches has never been greater. This consideration applies even more to the rather complex techniques of PDT and aPDI (antimicrobial photodynamic inactivation), than it does to the more traditional testing of new pharmaceutical or biologic therapies. The multi-target nature of anti-cancer PDT (tumour cells, tumour vasculature and immune response) means that thought must be given to un-

**Table 7 PDT for other disease indications**

Abbreviations: BPD-MA, benzoporphyrin derivative monoacid ring A; DLI, drug light interval; MB, methylene blue.

| Disease                      | Specialty        | Animal model                                                  | PDT regimen                                                                                    | References |
|------------------------------|------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------|
| Choroidal neovascularization | Ophthalmology    | Choriocapillary photo-occlusion in rabbits                    | Verteporfin BPD-MA, DLI 3 h, 692 nm, 10 J/cm <sup>2</sup>                                      | [103]      |
| Choroidal neovascularization | Ophthalmology    | Argon-laser-induced injuries to choroid in monkeys            | Verteporfin, liposomal BPD, DLI 50 min, 692 nm, 150 J/cm <sup>2</sup> , 600 mW/cm <sup>2</sup> | [104]      |
| Atherosclerosis              | Cardiology       | Balloon-injured arteries in cholesterol fed rabbits           | Etiopurpurin MV0611, DLI 24 h, 542 nm, 18 J/cm <sup>2</sup> , 90 s                             | [105]      |
| Atherosclerosis              | Cardiology       | Balloon-injured arteries in cholesterol-fed Yucatan miniswine | Photofrin, DLI 24 h, 630 nm, 240 J/cm <sup>2</sup> , 1.28 mW/cm <sup>2</sup> , 188 s           | [106]      |
| Atrial fibrillation          | Cardiology       | Intravascular ablation to block cavotricuspid isthmus in dogs | Talaporphin sodium, continuous infusion, 663 nm, 10 W/cm <sup>2</sup> , 30 s                   | [107]      |
| Atrial fibrillation          | Cardiology       | Atrioventricular block in rats                                | Talaporphin sodium, DLI 30 min, 670 nm, 10 J/cm <sup>2</sup> , 150 mW/cm <sup>2</sup>          | [108]      |
| Vascular wound healing       | Vascular surgery | Balloon-injured carotid arteries in rats                      | Local MB, 660 nm, 100 J/cm <sup>2</sup> , 100mW/cm <sup>2</sup>                                | [109]      |
| Wound healing                | Dermatology      | Excisional wounds in rats                                     | ALA IP, DLI 24 h, 632 nm, 3 J/cm <sup>2</sup> , 5 mW                                           | [110]      |
| Hypertrophic scars           | Dermatology      | Excisional wounds in ears of rabbits                          | Topical ALA, DLI 3 h, 635 nm, 114.6 J/cm <sup>2</sup> , 20 min                                 | [111]      |
| Photoaging                   | Dermatology      | UV irradiation of mouse skin 5 days/8 weeks                   | Topical ALA, DLI 4 h, 635 nm, 75 J/cm <sup>2</sup>                                             | [112]      |

derstanding the specific tumour biology of the model chosen. Moreover, since the light delivery is by definition a localized process, the anatomical location of orthotopic tumours becomes important.

When the testing of PDT in animal models of infectious disease is undertaken, some other points need to be considered. Firstly it is important to realize that human infections generally develop gradually from a relatively small initial infectious inoculum, rather than from a sudden large application of millions or tens of millions of CFU. Secondly, a high level of selectivity for microbial cells over host mammalian cells is needed, since the actual fraction by weight of microbial cells in even a serious infection is still very low. Thirdly, when the light is switched off, the generation of microbicidal ROS is halted and the microbial cells may be free to resume their growth unhindered.

The popularity of testing PDT for non-traditional indications involves designing animal models of non-cancer, non-infectious disease. A diverse assortment of conditions in cardiology, atherosclerosis, ophthalmology, neuroscience could in principle be treated with PDT.

Finally, for those laboratories that are not easily able to carry out studies on traditional mammalian animal models, there are new models described using invertebrate hosts and fertilized eggs. Large animal models have not been much studied in the PDT field, but as more new indications are being studied, studies on large animals can be expected to become more important.

## FUNDING

This work was supported by the CAPES-Ministry of Education, Brazil [grant number 99999.002158/ 2014-00 (to Z.S.S.)]; and the National Institute of Health [grant number R01AI050875 (to M.R.H.)].

## REFERENCES

- Agostinis, P, Berg, K., Cengel, K.A., Foster, T.H., Girotti, A.W., Gollnick, S.O., Hahn, S.M., Hamblin, M.R., Juzeniene, A., Kessel, D. et al. (2011) Photodynamic therapy of cancer: an update. *CA Cancer J. Clin.* **61**, 250–281 [CrossRef PubMed](#)
- Krammer, B. and Plaetzer, K. (2008) ALA and its clinical impact, from bench to bedside. *Photochem. Photobiol. Sci.* **7**, 283–289 [CrossRef PubMed](#)
- Diamond, I., Granelli, S.G., McDonagh, A.F., Nielsen, S., Wilson, C.B. and Jaenicke, R. (1972) Photodynamic therapy of malignant tumours. *Lancet* **2**, 1175–1177 [CrossRef PubMed](#)
- Dougherty, T.J., Grindey, G.B., Fiel, R., Weishaupt, K.R. and Boyle, D.G. (1975) Photoradiation therapy. II. cure of animal tumors with hematoporphyrin and light. *J. Natl. Cancer Inst.* **55**, 115–121 [PubMed](#)
- Antoni, D., Burckel, H., Josset, E. and Noel, G. (2015) Three-dimensional cell culture: a breakthrough *in vivo*. *Int. J. Mol. Sci.* **16**, 5517–5527 [CrossRef PubMed](#)

- 6 Yang, Y., Yang, X., Zou, J., Jia, C., Hu, Y., Du, H. and Wang, H. (2015) Evaluation of photodynamic therapy efficiency using an *in vitro* three-dimensional microfluidic breast cancer tissue model. *Lab. Chip.* **15**, 735–744 [CrossRef PubMed](#)
- 7 Ismail, M.S., Torsten, U., Dressler, C., Diederichs, J.E., Huske, S., Weitzel, H. and Berlien, H.P. (1999) Photodynamic therapy of malignant ovarian tumours cultivated on CAM. *Lasers Med. Sci.* **14**, 91–96 [CrossRef PubMed](#)
- 8 Hornung, R., Hammer-Wilson, M.J., Kimel, S., Liaw, L.H., Tadir, Y. and Berns, M.W. (1999) Systemic application of photosensitizers in the chick chorioallantoic membrane (CAM) model: photodynamic response of CAM vessels and 5-aminolevulinic acid uptake kinetics by transplantable tumors. *J. Photochem. Photobiol. B* **49**, 41–49 [CrossRef PubMed](#)
- 9 Hoppenheit, C., Huttenberger, D., Foth, H.J., Spitzer, W.J., Reichert, T.E. and Muller-Richter, U.D. (2006) Pharmacokinetics of the photosensitizers aminolevulinic acid and aminolevulinic acid hexylester in oro-facial tumors embedded in the chorioallantoic membrane of a hen's egg. *Cancer Biother. Radiopharm.* **21**, 569–578 [CrossRef PubMed](#)
- 10 Xiang, L., Xing, D., Gu, H., Yang, D., Yang, S., Zeng, L. and Chen, W.R. (2007) Real-time optoacoustic monitoring of vascular damage during photodynamic therapy treatment of tumor. *J. Biomed. Opt.* **12**, 014001 [CrossRef PubMed](#)
- 11 Garrier, J., Reshetov, V., Grafe, S., Guillemin, F., Zorin, V. and Bezdetnaya, L. (2013) Factors affecting the selectivity of nanoparticle-based photoinduced damage in free and xenografted chorioallantoic membrane model. *J. Drug Target*, in the press
- 12 Bonnotte, B., Gough, M., Phan, V., Ahmed, A., Chong, H., Martin, F. and Vile, R.G. (2003) Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. *Cancer Res.* **63**, 2145–2149 [PubMed](#)
- 13 Maas, A.L., Carter, S.L., Wileyto, E.P., Miller, J., Yuan, M., Yu, G., Durham, A.C. and Busch, T.M. (2012) Tumor vascular microenvironment determines responsiveness to photodynamic therapy. *Cancer Res.* **72**, 2079–2088 [CrossRef PubMed](#)
- 14 Peng, Q., Moan, J., Kongshaug, M., Evensen, J.F., Anholt, H. and Rimmington, C. (1991) Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. *Int. J. Cancer* **48**, 258–264 [CrossRef PubMed](#)
- 15 Gibson, S.L., van der Meid, K.R., Murant, R.S. and Hilf, R. (1990) Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of photofrin II. *Br. J. Cancer* **61**, 553–557 [CrossRef PubMed](#)
- 16 Luo, W.R. and Yao, K.T. (2014) Cancer stem cell characteristics, ALDH1 expression in the invasive front of nasopharyngeal carcinoma. *Virchows Archiv.* **464**, 35–43 [CrossRef](#)
- 17 Habu, S., Fukui, H., Shimamura, K., Kasai, M., Nagai, Y., Okumura, K. and Tamaoki, N. (1981) *In vivo* effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. *J. Immunol.* **127**, 34–38 [PubMed](#)
- 18 Shope, R.E. and Hurst, E.W. (1933) Infectious papillomatosis of rabbits: with a note on the histopathology. *J. Exp. Med.* **58**, 607–624 [CrossRef PubMed](#)
- 19 Nishiwaki, Y., Nakamura, S. and Sakaguchi, S. (1989) New method of photosensitizer accumulation for photodynamic therapy in an experimental liver tumor. *Lasers Surg. Med.* **9**, 254–263 [CrossRef PubMed](#)
- 20 Elliott, J.T., Samkoe, K.S., Gunn, J.R., Stewart, E.E., Gardner, T.B., Tichauer, K.M., Lee, T.Y., Hoopes, R.J., Pereira, S.P., Hasan, T. and Pogue, B.W. (2015) Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study. *Acad. Radiol.* **22**, 572–579 [CrossRef PubMed](#)
- 21 Xiao, H., Liao, Q., Cheng, M., Li, F., Xie, B., Li, M. and Feng, H. (2009) 5-Amino-4-oxopentanoic acid photodynamic diagnosis guided microsurgery and photodynamic therapy on VX2 brain tumour implanted in a rabbit model. *Chin. Med. J.* **122**, 1316–1321 [PubMed](#)
- 22 Ruggeri, B.A., Camp, F. and Miknyoczki, S. (2014) Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. *Biochem. Pharmacol.* **87**, 150–161 [CrossRef PubMed](#)
- 23 Vairaktaris, E., Spyridonidou, S., Papakosta, V., Vylliotis, A., Lazaris, A., Perrea, D., Yapijakis, C. and Patsouris, E. (2008) The hamster model of sequential oral oncogenesis. *Oral Oncol.* **44**, 315–324 [CrossRef PubMed](#)
- 24 Lee, H. (2014) Genetically engineered mouse models for drug development and preclinical trials. *Biomol. Ther.* **22**, 267–274 [CrossRef](#)
- 25 Frese, K.K. and Tuveson, D.A. (2007) Maximizing mouse cancer models. *Nat. Rev. Cancer* **7**, 645–658 [CrossRef PubMed](#)
- 26 Beard, C., Hochedlinger, K., Plath, K., Wutz, A. and Jaenisch, R. (2006) Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. *Genesis* **44**, 23–28 [CrossRef PubMed](#)
- 27 Koba, W., Jelicks, L.A. and Fine, E.J. (2013) MicroPET/SPECT/CT imaging of small animal models of disease. *Am. J. Pathol.* **182**, 319–324 [CrossRef PubMed](#)
- 28 Jang, B.S. (2013) MicroSPECT and MicroPET imaging of small animals for drug development. *Toxicol. Res.* **29**, 1–6 [CrossRef PubMed](#)
- 29 Schambach, S.J., Bag, S., Schilling, L., Groden, C. and Brockmann, M.A. (2010) Application of micro-CT in small animal imaging. *Methods* **50**, 2–13 [CrossRef PubMed](#)
- 30 Renault, G., Bonnin, P., Marchiol-Fournigault, C., Gregoire, J.M., Serriere, S., Richard, B. and Fradelizi, D. (2006) High-resolution ultrasound imaging of the mouse. *J. Radiol.* **87**, 1937–1945 [CrossRef PubMed](#)
- 31 Xia, J. and Wang, L.V. (2014) Small-animal whole-body photoacoustic tomography: a review. *IEEE Trans. Biomed. Eng.* **61**, 1380–1389 [CrossRef PubMed](#)
- 32 O'Neill, J. (2015) *Tackling a Global Health Crisis: Initial Steps*. Wellcome Trust, London
- 33 Demidova, T.N., Gad, F., Zahra, T., Francis, K.P. and Hamblin, M.R. (2005) Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. *J. Photochem. Photobiol. B* **81**, 15–25 [CrossRef PubMed](#)
- 34 Hamblin, M.R., O'Donnell, D.A., Murthy, N., Contag, C.H. and Hasan, T. (2002) Rapid control of wound infections by targeted photodynamic therapy monitored by *in vivo* bioluminescence imaging. *Photochem. Photobiol.* **75**, 51–57 [CrossRef PubMed](#)
- 35 Glavis-Bloom, J., Muhammed, M. and Mylonakis, E. (2012) Of model hosts and man: using *Caenorhabditis elegans*, *Drosophila melanogaster* and *Galleria mellonella* as model hosts for infectious disease research. *Adv. Exp. Med. Biol.* **710**, 11–17 [CrossRef PubMed](#)
- 36 Chibebe, Jr, J., Fuchs, B.B., Sabino, C.P., Junqueira, J.C., Jorge, A.O., Ribeiro, M.S., Gilmore, M.S., Rice, L.B., Tegos, G.P., Hamblin, M.R. and Mylonakis, E. (2013) Photodynamic and antibiotic therapy impair the pathogenesis of *Enterococcus faecium* in a whole animal insect model. *PLoS One* **8**, e55926 [CrossRef PubMed](#)
- 37 Chibebe Junior, J., Sabino, C.P., Tan, X., Junqueira, J.C., Wang, Y., Fuchs, B.B., Jorge, A.O., Tegos, G.P., Hamblin, M.R. and Mylonakis, E. (2013) Selective photoinactivation of *Candida albicans* in the non-vertebrate host infection model *Galleria mellonella*. *BMC Microbiol.* **13**, 217 [CrossRef PubMed](#)
- 38 Korbelik, M., Krosli, G., Krosli, J. and Dougherty, G.J. (1996) The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. *Cancer Res.* **56**, 5647–5652 [PubMed](#)



- 39 Belicha-Villanueva, A., Riddell, J., Bangia, N. and Gollnick, S.O. (2012) The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules. *Lasers Surg. Med.* **44**, 60–68 [CrossRef PubMed](#)
- 40 Blank, M., Lavie, G., Mandel, M. and Keisari, Y. (2000) Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. *Oncol. Res.* **12**, 409–418 [PubMed](#)
- 41 Canti, G., Lattuada, D., Nicolini, A., Taroni, P., Valentini, G. and Cubeddu, R. (1994) Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light. *Anticancer Drugs* **5**, 443–447 [CrossRef PubMed](#)
- 42 Tong, Z.S., Miao, P.T., Liu, T.T., Jia, Y.S. and Liu, X.D. (2012) Enhanced antitumor effects of BPD-MA-mediated photodynamic therapy combined with adriamycin on breast cancer in mice. *Acta Pharmacol. Sin.* **33**, 1319–1324 [CrossRef PubMed](#)
- 43 Skidan, I., Dholakia, P. and Torchilin, V. (2008) Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphyrin-loaded PEG-PE micelles. *J. Drug Target.* **16**, 486–493 [CrossRef PubMed](#)
- 44 Merchant, S., Huang, N. and Korbelik, M. (2010) Expression of complement and pentraxin proteins in acute phase response elicited by tumor photodynamic therapy: the engagement of adrenal hormones. *Int. Immunopharmacol.* **10**, 1595–1601 [CrossRef PubMed](#)
- 45 Kim, Y.W., Bae, S.M., Liu, H.B., Kim, I.W., Chun, H.J. and Ahn, W.S. (2012) Selenium enhances the efficacy of Radachlorin mediated-photodynamic therapy in TC-1 tumor development. *Oncol. Rep.* **28**, 576–584 [PubMed](#)
- 46 Adams, K., Rainbow, A.J., Wilson, B.C. and Singh, G. (1999) *In vivo* resistance to photofrin-mediated photodynamic therapy in radiation-induced fibrosarcoma cells resistant to *in vitro* photofrin-mediated photodynamic therapy. *J. Photochem. Photobiol. B* **49**, 136–141 [CrossRef PubMed](#)
- 47 Korbelik, M., Sun, J. and Zeng, H. (2003) Ischaemia-reperfusion injury in photodynamic therapy-treated mouse tumours. *Br. J. Cancer* **88**, 760–766 [CrossRef PubMed](#)
- 48 Separovic, D., Bielawski, J., Pierce, J.S., Merchant, S., Tarca, A.L., Bhatti, G., Ogretmen, B. and Korbelik, M. (2011) Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response. *Int. J. Oncol.* **38**, 521–527 [CrossRef PubMed](#)
- 49 Satonaka, H., Kusuzaki, K., Matsubara, T., Shintani, K., Nakamura, T., Matsumine, A., Iino, T. and Uchida, A. (2010) *In vivo* anti-tumor activity of photodynamic therapy with intravenous administration of acridine orange, followed by illumination with high-power flash wave light in a mouse osteosarcoma model. *Oncol. Lett.* **1**, 69–72 [PubMed](#)
- 50 Mroz, P., Vatansever, F., Muchowicz, A. and Hamblin, M.R. (2013) Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. *Cancer Res.* **73**, 6462–6470 [CrossRef PubMed](#)
- 51 Gamaleia, N.F., Lisnyak, I.A., Shishko, E.D., Mamchur, A.A., Prokopenko, I.V. and Kholin, V.V. (2012) Chronobiological approaches to antiangiogenic photodynamic therapy of tumors: the first experimental evaluation. *Exp. Oncol.* **34**, 364–366 [PubMed](#)
- 52 Gil, M., Bieniasz, M., Seshadri, M., Fisher, D., Ciesielski, M.J., Chen, Y., Pandey, R.K. and Kozbor, D. (2011) Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. *Br. J. Cancer* **105**, 1512–1521 [CrossRef PubMed](#)
- 53 Lindsay, E.A., Berenbaum, M.C., Bonnett, R. and Thomas, D.G. (1991) Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. *Br. J. Cancer* **63**, 242–246 [CrossRef PubMed](#)
- 54 Nenu, I., Popescu, T., Aldea, M.D., Craciun, L., Olteanu, D., Tatomir, C., Bolfa, P., Ion, R.M., Muresan, A. and Filip, A.G. (2014) Metformin associated with photodynamic therapy—a novel oncological direction. *J. Photochem. Photobiol. B* **138**, 80–91 [CrossRef PubMed](#)
- 55 Momma, T., Hamblin, M.R., Wu, H.C. and Hasan, T. (1998) Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. *Cancer Res.* **58**, 5425–5431 [PubMed](#)
- 56 Kammerer, R., Buchner, A., Palluch, P., Pongratz, T., Oboukhovskij, K., Beyer, W., Johansson, A., Stepp, H., Baumgartner, R. and Zimmermann, W. (2011) Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. *PLoS One* **6**, e21834 [CrossRef PubMed](#)
- 57 Francois, A., Salvadori, A., Bressenot, A., Bezdetyaya, L., Guillemin, F. and D'Hallewin, M.A. (2013) How to avoid local side effects of bladder photodynamic therapy: impact of the fluence rate. *J. Urol.* **190**, 731–736 [CrossRef PubMed](#)
- 58 Chen, B., Pogue, B.W., Zhou, X., O'Hara, J.A., Solban, N., Demidenko, E., Hoopes, P.J. and Hasan, T. (2005) Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. *Clin. Cancer Res.* **11**, 720–727 [PubMed](#)
- 59 Meyers, J.D., Cheng, Y., Broome, A.M., Agnes, R.S., Schluchter, M.D., Margevicius, S., Wang, X., Kenney, M.E., Burda, C. and Basilion, J.P. (2015) Peptide-targeted gold nanoparticles for photodynamic therapy of brain cancer. *Part. Part. Syst. Charact.* **32**, 448–457 [CrossRef PubMed](#)
- 60 Wang, X., Hu, J., Wang, P., Zhang, S., Liu, Y., Xiong, W. and Liu, Q. (2015) Analysis of the *in vivo* and *in vitro* effects of photodynamic therapy on breast cancer by using a sensitizer, sinoporphyrin sodium. *Theranostics* **5**, 772–786 [CrossRef PubMed](#)
- 61 Olivier, D., Bourre, L., El-Sabbagh, E., Loussouarn, D., Simonneaux, G., Valette, F. and Patrice, T. (2007) Photodynamic effects of SIM01, a new sensitizer, on experimental brain tumors in rats. *Surg. Neurol.* **68**, 255–263 [CrossRef PubMed](#)
- 62 Angell-Petersen, E., Spetälén, S., Madsen, S.J., Sun, C.H., Peng, Q., Carper, S.W., Sioud, M. and Hirschberg, H. (2006) Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. *J. Neurosurg.* **104**, 109–117 [CrossRef PubMed](#)
- 63 Peterson, C.M., Reed, R., Jolles, C.J., Jones, K.P., Straight, R.C. and Poulson, A.M. (1992) Photodynamic therapy of human ovarian epithelial carcinoma, OVCAR-3, heterotransplanted in the nude mouse. *Am. J. Obstet. Gynecol.* **167**, 1852–1855 [CrossRef PubMed](#)
- 64 Molpus, K.L., Kato, D., Hamblin, M.R., Lilge, L., Bamberg, M. and Hasan, T. (1996) Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. *Cancer Res.* **56**, 1075–1082 [PubMed](#)
- 65 Samkoe, K.S., Chen, A., Rizvi, I., O'Hara, J.A., Hoopes, P.J., Pereira, S.P., Hasan, T. and Pogue, B.W. (2010) Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. *Int. J. Radiat. Oncol. Biol. Phys.* **76**, 251–259 [CrossRef PubMed](#)
- 66 Kosharsky, B., Solban, N., Chang, S.K., Rizvi, I., Chang, Y. and Hasan, T. (2006) A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. *Cancer Res.* **66**, 10953–10958 [CrossRef PubMed](#)
- 67 Koudinova, N.V., Pinthus, J.H., Brandis, A., Brenner, O., Bendel, P., Ramon, J., Eshhar, Z., Scherz, A. and Salomon, Y. (2003) Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful *in vivo* treatment of human prostatic small cell carcinoma xenografts. *J. Int. Cancer* **104**, 782–789 [CrossRef](#)
- 68 Wu, D., Liu, Z., Fu, Y., Zhang, Y., Tang, N., Wang, Q. and Tao, L. (2013) Efficacy of 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a in photodynamic therapy of human esophageal squamous cancer cells. *Oncol. Lett.* **6**, 1111–1119 [PubMed](#)

- 69 Cheng, J., Xu, J., Duanmu, J., Zhou, H., Booth, C.J. and Hu, Z. (2011) Effective treatment of human lung cancer by targeting tissue factor with a factor VII-targeted photodynamic therapy. *Curr. Cancer Drug Targets* **11**, 1069–1081 [CrossRef PubMed](#)
- 70 Grossman, C.E., Pickup, S., Durham, A., Wileyto, E.P., Putt, M.E. and Busch, T.M. (2011) Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model. *Lasers Surg. Med.* **43**, 663–675 [PubMed](#)
- 71 Sutoris, K., Vetvicka, D., Horak, L., Benes, J., Nekvasil, M., Jezek, P., Zadinova, M. and Pouckova, P. (2012) Evaluation of topical photodynamic therapy of mammary carcinoma with an experimental gel containing liposomal hydroxyl-aluminium phthalocyanine. *Anticancer Res.* **32**, 3769–3774 [PubMed](#)
- 72 Dolmans, D.E., Kadambi, A., Hill, J.S., Flores, K.R., Gerber, J.N., Walker, J.P., Borel Rinkes, I.H., Jain, R.K. and Fukumura, D. (2002) Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. *Cancer Res.* **62**, 4289–4294 [PubMed](#)
- 73 Del Governatore, M., Hamblin, M.R., Shea, C.R., Rizvi, I., Molpus, K.G., Tanabe, K.K. and Hasan, T. (2000) Experimental photoinmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. *Cancer Res.* **60**, 4200–4205 [PubMed](#)
- 74 Xie, Y., Wei, Z.B., Zhang, Z., Wen, W. and Huang, G.W. (2009) Effect of 5-ALA-PDT on VEGF and PCNA expression in human NPC-bearing nude mice. *Oncol. Rep.* **22**, 1365–1371 [CrossRef PubMed](#)
- 75 Nauta, J.M., van Leengoed, H.L., Witjes, M.J., Nikkels, P.G., Star, W.M., Vermey, A. and Roodenburg, J.L. (1997) Photofrin-mediated photodynamic therapy of chemically-induced premalignant lesions and squamous cell carcinoma of the palatal mucosa in rats. *Int. J. Oral Maxillofac. Surg.* **26**, 223–231 [CrossRef PubMed](#)
- 76 Ma, G., Ikeda, H., Inokuchi, T. and Sano, K. (1999) Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue. *Oral Oncol.* **35**, 120–124 [CrossRef PubMed](#)
- 77 Hsu, Y.C., Yang, D.F., Chiang, C.P., Lee, J.W. and Tseng, M.K. (2012) Successful treatment of 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch precancerous lesions by topical 5-aminolevulinic acid-mediated photodynamic therapy. *Photodiagnosis Photodyn. Ther.* **9**, 310–318 [CrossRef PubMed](#)
- 78 Ferreira, I., Ferreira, J., Vollet-Filho, J.D., Moriyama, L.T., Bagnato, V.S., Salvadori, D.M. and Rocha, N.S. (2013) Photodynamic therapy for the treatment of induced mammary tumor in rats. *Lasers Med. Sci.* **28**, 571–577 [CrossRef PubMed](#)
- 79 Kwitniewski, M., Jankowski, D., Jaskiewicz, K., Dziadziuszko, H., Juzeniene, A., Moan, J., Ma, L.W., Peksa, R., Kunikowska, D., Graczyk, A. et al. (2009) Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. *Int. J. Cancer* **125**, 1721–1727 [CrossRef PubMed](#)
- 80 Boiy, A., Roelandts, R. and de Witte, P.A. (2011) Photodynamic therapy using topically applied hypericin: comparative effect with methyl-aminolevulinic acid on UV induced skin tumours. *J. Photochem. Photobiol. B* **102**, 123–131 [CrossRef PubMed](#)
- 81 Walt, H., Nap, M., Dorward, A.M., Leers, M.P., Tennent, B.J., Varga, Z., Stallmach, T., Björklund, V. and Beamer, W.G. (2006) Early apoptotic responses in transgenic mouse mammary carcinoma for photodynamic therapy. *Photodiagnosis Photodyn. Ther.* **3**, 227–233 [CrossRef PubMed](#)
- 82 Dorward, A.M., Fancher, K.S., Duffy, T.M., Beamer, W.G. and Walt, H. (2005) Early neoplastic and metastatic mammary tumours of transgenic mice detected by 5-aminolevulinic acid-stimulated protoporphyrin IX accumulation. *Br. J. Cancer* **93**, 1137–1143 [CrossRef PubMed](#)
- 83 Abd-Elgaliel, W.R., Cruz-Monserrate, Z., Wang, H., Logsdon, C.D. and Tung, C.H. (2013) Pancreatic cancer-associated Cathepsin E as a drug activator. *J. Control. Release* **167**, 221–227 [CrossRef PubMed](#)
- 84 Caty, V., Liu, Y., Viau, G. and Bissonnette, R. (2006) Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice. *Br. J. Dermatol.* **154**, 740–742 [PubMed](#)
- 85 Cordoba, F., Braathen, L.R., Weissenberger, J., Vallan, C., Kato, M., Nakashima, I., Weis, J. and von Felbert, V. (2005) 5-aminolaevulinic acid photodynamic therapy in a transgenic mouse model of skin melanoma. *Exp. Dermatol.* **14**, 429–437 [CrossRef PubMed](#)
- 86 Komoike, N., Kato, T., Saijo, H., Arihiro, S., Hashimoto, H., Okabe, M., Ito, M., Koido, S., Homma, S. and Tajiri, H. (2013) Photodynamic diagnosis of colitis-associated dysplasia in a mouse model after oral administration of 5-aminolevulinic acid. *In Vivo* **27**, 747–753
- 87 Berthiaume, F., Reiken, S.R., Toner, M., Tompkins, R.G. and Yarmush, M.L. (1994) Antibody-targeted photolysis of bacteria *in vivo*. *Biotechnology* **12**, 703–706 [CrossRef PubMed](#)
- 88 Orenstein, A., Klein, D., Kopolovic, J., Winkler, E., Malik, Z., Keller, N. and Nitzan, Y. (1997) The use of porphyrins for eradication of *Staphylococcus aureus* in burn wound infections. *FEMS Immunol. Med. Microbiol.* **19**, 307–314 [CrossRef PubMed](#)
- 89 Hamblin, M.R., O'Donnell, D.A., Murthy, N., Rajagopalan, K., Michaud, N., Sherwood, M.E. and Hasan, T. (2002) Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria. *J. Antimicrob. Chemother.* **49**, 941–951 [CrossRef PubMed](#)
- 90 Hamblin, M.R., Zahra, T., Contag, C.H., McManus, A.T. and Hasan, T. (2003) Optical monitoring and treatment of potentially lethal wound infections *in vivo*. *J. Infect. Dis.* **187**, 1717–1725 [CrossRef PubMed](#)
- 91 Gad, F., Zahra, T., Francis, K.P., Hasan, T. and Hamblin, M.R. (2004) Targeted photodynamic therapy of established soft-tissue infections in mice. *Photochem. Photobiol. Sci.* **3**, 451–458 [CrossRef PubMed](#)
- 92 Lambrechts, S.A., Demidova, T.N., Aalders, M.C., Hasan, T. and Hamblin, M.R. (2005) Photodynamic therapy for *Staphylococcus aureus* infected burn wounds in mice. *Photochem. Photobiol. Sci.* **4**, 503–509 [CrossRef PubMed](#)
- 93 Dai, T., Tegos, G.P., Lu, Z., Huang, L., Zhiyentayev, T., Franklin, M.J., Baer, D.G. and Hamblin, M.R. (2009) Photodynamic therapy for *Acinetobacter baumannii* burn infections in mice. *Antimicrob. Agents Chemother.* **53**, 3929–3934 [CrossRef PubMed](#)
- 94 Teichert, M.C., Jones, J.W., Usacheva, M.N. and Biel, M.A. (2002) Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **93**, 155–160 [CrossRef PubMed](#)
- 95 Pelloi, L.S., Biondo, C.E., Kimura, E., Politi, M.J., Lonardonì, M.V., Aristides, S.M., Dorea, R.C., Hioka, N. and Silveira, T.G. (2011) Photodynamic therapy for American cutaneous leishmaniasis: the efficacy of methylene blue in hamsters experimentally infected with *Leishmania (Leishmania) amazonensis*. *Exp. Parasitol.* **128**, 353–356 [CrossRef PubMed](#)
- 96 O'Riordan, K., Sharlin, D.S., Gross, J., Chang, S., Errabelli, D., Akilov, O.E., Kosaka, S., Nau, G.J. and Hasan, T. (2006) Photoinactivation of mycobacteria *in vitro* and in a new murine model of localized *Mycobacterium bovis* BCG-induced granulomatous infection. *Antimicrob. Agents Chemother.* **50**, 1828–1834 [CrossRef PubMed](#)



- 97 Jung, J.Y., Kwon, P.S., Ahn, J.C., Ge, R., Suh, M.W. and Rhee, C.K. (2009) *In vitro* and *in vivo* photodynamic therapy of otitis media in gerbils. *Laryngoscope* **119**, 1781–1787 [CrossRef PubMed](#)
- 98 Fernandes, L.A., de Almeida, J.M., Theodoro, L.H., Bosco, A.F., Nagata, M.J., Martins, T.M., Okamoto, T. and Garcia, V.G. (2009) Treatment of experimental periodontal disease by photodynamic therapy in immunosuppressed rats. *J. Clin. Periodontol.* **36**, 219–228 [CrossRef PubMed](#)
- 99 Bisland, S.K., Chien, C., Wilson, B.C. and Burch, S. (2006) Pre-clinical *in vitro* and *in vivo* studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. *Photochem. Photobiol. Sci.* **5**, 31–38 [CrossRef PubMed](#)
- 100 Tanaka, M., Mroz, P., Dai, T., Huang, L., Morimoto, Y., Kinoshita, M., Yoshihara, Y., Nemoto, K., Shinomiya, N., Seki, S. and Hamblin, M.R. (2012) Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation. *PLoS One* **7**, e39823 [CrossRef PubMed](#)
- 101 Lin, J., Bi, L.J., Zhang, Z.G., Fu, Y.M. and Dong, T.T. (2010) Toluidine blue-mediated photodynamic therapy of oral wound infections in rats. *Lasers Med. Sci.* **25**, 233–238 [CrossRef PubMed](#)
- 102 Wong, T.W., Wang, Y.Y., Sheu, H.M. and Chuang, Y.C. (2005) Bactericidal effects of toluidine blue-mediated photodynamic action on *Vibrio vulnificus*. *Antimicrob. Agents Chemother.* **49**, 895–902 [CrossRef PubMed](#)
- 103 Schmidt-Erfurth, U., Hasan, T., Gragoudas, E., Michaud, N., Flotte, T.J. and Birngruber, R. (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. *Ophthalmology* **101**, 1953–1961 [CrossRef PubMed](#)
- 104 Kramer, M., Miller, J.W., Michaud, N., Moulton, R.S., Hasan, T., Flotte, T.J. and Gragoudas, E.S. (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. selective treatment of choroidal neovascularization in monkeys. *Ophthalmology* **103**, 427–438 [CrossRef PubMed](#)
- 105 Waksman, R., McEwan, P.E., Moore, T.I., Pakala, R., Kolodgie, F.D., Hellings, D.G., Seabron, R.C., Rychnovsky, S.J., Vasek, J., Scott, R.W. and Virmani, R. (2008) PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. *J. Am. Coll. Cardiol.* **52**, 1024–1032 [CrossRef PubMed](#)
- 106 Hsiang, Y.N., Todd, M.E. and Bower, R.D. (1995) Determining light dose for photodynamic therapy of atherosclerotic lesions in the Yucatan miniswine. *J. Endovasc. Surg.* **2**, 365–371 [CrossRef PubMed](#)
- 107 Kimura, T., Takatsuki, S., Miyoshi, S., Fukumoto, K., Takahashi, M., Ogawa, E., Ito, A., Arai, T., Ogawa, S. and Fukuda, K. (2013) Nonthermal cardiac catheter ablation using photodynamic therapy. *Circ. Arrhythm. Electrophysiol.* **6**, 1025–1031 [CrossRef PubMed](#)
- 108 Ito, A., Hosokawa, S., Miyoshi, S., Soejima, K. and Arai, T. (2008) Photosensitization reaction-induced electrical blockade in myocardial tissue. *Conf. Proc. IEEE Eng. Med. Biol. Soc.* **2008**, 4361–4363 [PubMed](#)
- 109 Heckenkamp, J., Adili, F., Kishimoto, J., Koch, M. and Lamuraglia, G.M. (2000) Local photodynamic action of methylene blue favorably modulates the postinterventional vascular wound healing response. *J. Vasc. Surg.* **31**, 1168–1177 [CrossRef PubMed](#)
- 110 Jayasree, R.S., Gupta, A.K., Rathinam, K., Mohanan, P.V. and Mohanty, M. (2001) The influence of photodynamic therapy on the wound healing process in rats. *J. Biomater. Appl.* **15**, 176–186 [CrossRef PubMed](#)
- 111 Wang, Q., Dong, Y., Geng, S., Su, H., Ge, W. and Zhen, C. (2014) Photodynamic therapy inhibits the formation of hypertrophic scars in rabbit ears by regulating metalloproteinases and tissue inhibitor of metalloproteinase-1. *Clin. Exp. Dermatol.* **39**, 196–201 [CrossRef PubMed](#)
- 112 Park, J.Y., Jang, Y.H., Kim, Y.S., Sohn, S. and Kim, Y.C. (2013) Ultrastructural changes in photorejuvenation induced by photodynamic therapy in a photoaged mouse model. *Eur. J. Dermatol.* **23**, 471–477 [PubMed](#)

---

Received 22 July 2015/17 September 2015; accepted 25 September 2015

---

Version of Record published 28 September 2015, doi 10.1042/BSR20150188

---